Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
Sponsor: Design Therapeutics, Inc.
Summary
This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.
Official title: A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2025-02
Completion Date
2025-12
Last Updated
2025-02-21
Healthy Volunteers
Yes
Conditions
Interventions
DT-216P2
DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.
Saline
Normal saline solution will be used as placebo control.
Locations (1)
Nucleus Network, Level 5, 89 Commercial Road
Melbourne, Victoria, Australia